Informa Life Sciences is part of the Knowledge and Networking Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 3099067.

Informa
7:00am - 8:00am

Registration

More
Showing of Streams
9:45am - 10:10am

Morning Coffee & Networking

More
Showing of Streams
Showing of Streams
2:30pm - 3:15pm

Afternoon Coffee and Networking

More
Showing of Streams
5:15pm - 6:45pm

Grand Opening of the Poster & Exhibit Hall and Cocktail Reception

More
7:00am - 8:00am 60 mins
Registration
8:00am - 8:15am 15 mins
Cell, Gene and CART Therapy Bioprocessing
Chairperson's Opening Remarks
8:00am - 8:15am 15 mins
Cell, Gene and CART Therapy Commercialization
Chairperson's Opening Remarks
8:00am - 8:15am 15 mins
Pre-clinical and Clinical Development for Cell, Gene and CART Therapies
Chairperson's Opening Remarks
8:15am - 8:45am 30 mins
Info
Cell, Gene and CART Therapy Bioprocessing
Innovative solutions from Industry 4.0
  • Jian Irish - Global Head of Manufacturing, Kite Pharma, USA

    • Experience being among the first to launch a commercially-approved cellular therapy treatment
    • Scaling cellular therapy manufacturing from single-site to a decentralized network of global sites
    • Applying Industry 4.0 and automation opportunities in autologous cellular therapy manufacturing
8:15am - 8:45am 30 mins
Info
Cell, Gene and CART Therapy Commercialization
Innovative solutions from Industry 4.0
  • Jian Irish - Global Head of Manufacturing, Kite Pharma, USA

    • Experience being among the first to launch a commercially-approved cellular therapy treatment
    • Scaling cellular therapy manufacturing from single-site to a decentralized network of global sites
    • Applying Industry 4.0 and automation opportunities in autologous cellular therapy manufacturing
8:15am - 8:45am 30 mins
Info
Pre-clinical and Clinical Development for Cell, Gene and CART Therapies
Innovative solutions from Industry 4.0
  • Jian Irish - Global Head of Manufacturing, Kite Pharma, USA

    • Experience being among the first to launch a commercially-approved cellular therapy treatment
    • Scaling cellular therapy manufacturing from single-site to a decentralized network of global sites
    • Applying Industry 4.0 and automation opportunities in autologous cellular therapy manufacturing
8:45am - 9:15am 30 mins
Info
Cell, Gene and CART Therapy Bioprocessing
Designing production facilities of the future
  • John Heffernan - V.P. Commercial Manufacturing, Astellas
  • Case study
  • How can facilities be produced to meet the potential demand of cell and viral vectors
  • What needs to change and what innovations are being made
8:45am - 9:15am 30 mins
Info
Cell, Gene and CART Therapy Commercialization
Designing production facilities of the future
  • John Heffernan - V.P. Commercial Manufacturing, Astellas
  • Case study
  • How can facilities be produced to meet the potential demand of cell and viral vectors
  • What needs to change and what innovations are being made
8:45am - 9:15am 30 mins
Info
Pre-clinical and Clinical Development for Cell, Gene and CART Therapies
Designing production facilities of the future
  • John Heffernan - V.P. Commercial Manufacturing, Astellas
  • Case study
  • How can facilities be produced to meet the potential demand of cell and viral vectors
  • What needs to change and what innovations are being made
9:15am - 9:45am 30 mins
Cell, Gene and CART Therapy Bioprocessing
Designing the Cell Therapy Facility of the Future by Learning from the Past
  • Geoffrey Hodge - Chief Technical Officer, Unum Therapeutics
9:15am - 9:45am 30 mins
Cell, Gene and CART Therapy Commercialization
Designing the Cell Therapy Facility of the Future by Learning from the Past
  • Geoffrey Hodge - Chief Technical Officer, Unum Therapeutics
9:15am - 9:45am 30 mins
Pre-clinical and Clinical Development for Cell, Gene and CART Therapies
Designing the Cell Therapy Facility of the Future by Learning from the Past
  • Geoffrey Hodge - Chief Technical Officer, Unum Therapeutics
9:45am - 10:10am 25 mins
Morning Coffee & Networking
10:10am - 10:15am 5 mins
Cell, Gene and CART Therapy Bioprocessing
Chairperson's Opening Remarks
  • Nick Timmins, PhD - Vice President, Process Science, Bluerock Therapeutics
10:10am - 10:15am 5 mins
Cell, Gene and CART Therapy Commercialization
Chairperson's Opening Remarks
  • Ohad Karnieli, Ph.D., MBA - CEO, Atvio Biotech
10:10am - 10:15am 5 mins
Pre-clinical and Clinical Development for Cell, Gene and CART Therapies
Chairperson's Opening Remarks
  • Amritha Jaishankar - Associate Director, MD Stem Cell Research Fund, USA
10:15am - 10:45am 30 mins
Info
Cell, Gene and CART Therapy Bioprocessing
Automation of qPCR and ELISA assays for determination of AAV vector titre – a case study
  • Franz Schnetzinger - Director Analytical Development, Gyroscrope, UK
  • Introduction to qPCR and ELISA assay and method performance (manual vs pipetting robot)
  • Design principles to reduce variation and increase throughput
  • Automation of data analysis & trending
  • Advantages of automation  & points to consider when embarking on automation route
10:15am - 11:15am 60 mins
Info
Cell, Gene and CART Therapy Commercialization
Discussion Panel: Outsourcing vs. Insourcing – What is the best path to take?
  • Chris Gemmiti, Ph.D. - Head of Operations, Sentien Biotechnologies Inc.
  • Marcos Langtry - Outsourced Manufacturing and Development Director, TiGenix, Belgium
  • Sanjin Zvonić - VP Process Science and Manufacturing, WindMIL Therapeutics, USA

Looking for 3-5 panellists to join this session that will be looking at:

 

  • Outsourcing models for cell and gene therapies
  • Auto vs. allo
  • What is the best timeline if you are considering outsourcing?
  • When to make the call and make the move?
  • Should a CMO be used early phase? Or once you reach BLA?
  • Why wouldn’t you outsource?
  • Are there different solutions dependent on product type?
  • Does one choice result in a more financially viable product?
10:15am - 10:45am 30 mins
Info
Pre-clinical and Clinical Development for Cell, Gene and CART Therapies
Technology showcase – What are the latest and greatest applications for genetically modifying cells, T cells or AAV?
  • Gabriele Proetzl - Director, Regenerative Medicine, Takeda, USA (pending final confirmation)


  • How to do this in a sustainable, scalable manner
  • Do these options offer an opportunity to mitigate concerns around scalable manufacturing?
10:45am - 11:15am 30 mins
Cell, Gene and CART Therapy Bioprocessing
Discovering Critical Quality Attributes for Cell Therapy Manufacture Using Machine Learning
  • Dan Wilkinson - Computational Biologist, BlueRock Therapeutics, USA
10:45am - 11:15am 30 mins
Pre-clinical and Clinical Development for Cell, Gene and CART Therapies
Developing new AAV vectors that can cross the blood brain barrier
  • Miguel Esteves - Associate Professor, Horae Gene Therapy Center, University of Massachusetts Medical School , USA
11:15am - 11:45am 30 mins
Info
Cell, Gene and CART Therapy Bioprocessing
Molecular characterization of gene therapy vectors - digital PCR is already here, high-throughput sequencing is next in line
  • David Dobnik - Scientific Associate, National Institute of Biology, Slovenia
  • Moving from qPCR to digital PCR
  • Identification of nucleic acid impurities and their localization
  • High-throughput sequencing for thorough characterization of nucleic acid content
11:15am - 11:45am 30 mins
Info
Cell, Gene and CART Therapy Commercialization
Technology evaluation – when and how to innovate?
  • Lior Raviv - Vice President, Pluristem Therapeutics Inc.
  • Feedback and examples of when a manufacturer has successfully worked with technology platforms to advance timelines and drive towards commercialization of a product
11:15am - 11:45am 30 mins
Pre-clinical and Clinical Development for Cell, Gene and CART Therapies
Machine-guided engineering of AAV capsids for gene therapy
  • Eric Kelsic - Co-Founder & CEO, Dyno Therapeutics, USA
11:45am - 12:20pm 35 mins
Info
Cell, Gene and CART Therapy Bioprocessing
Spotlight Presentation

Use this event to raise your corporate profile and demonstrate your products and services to our targeted, multidisciplinary audience. By joining us in sponsoring and exhibiting at this event, you will be able to:

  • Use an exhibition stand to meet new clients in the main networking area
  • Raise your corporate profile and shape your corporate image with logo placement
  • Ensure market presence as a thought leader with a speaking position

For sponsorship and exhibition opportunities please contact: Kristin Skahan; Email: kristin.skahan@knect365.com


 

11:45am - 12:20pm 35 mins
Info
Cell, Gene and CART Therapy Commercialization
Spotlight Presentation

 Use this event to raise your corporate profile and demonstrate your products and services to our targeted, multidisciplinary audience. By joining us in sponsoring and exhibiting at this event, you will be able to:

  • Use an exhibition stand to meet new clients in the main networking area
  • Raise your corporate profile and shape your corporate image with logo placement
  • Ensure market presence as a thought leader with a speaking position

For sponsorship and exhibition opportunities please contact: Kristin Skahan; Email: kristin.skahan@knect365.com

 

11:45am - 12:15pm 30 mins
Info
Pre-clinical and Clinical Development for Cell, Gene and CART Therapies
Exosomes and their potential for scalable manufacturing platforms
  • Jon A. Rowley, Ph.D. - Chief Executive & Technology Officer, RoosterBio Inc.
  • Feedback on clinical advancement
  • Transition from bench-scale to clinical production
  • Do they offer a potentially scalable manufacturing platform?
1:25pm - 1:55pm 30 mins
Cell, Gene and CART Therapy Bioprocessing
CART Drug Product Characterization Using a Combination of High Dimensional Analysis
  • Eric Alonzo - Scientist, Cellular Analytics, Bluebird Bio
1:30pm - 2:00pm 30 mins
Cell, Gene and CART Therapy Commercialization
Scaling up gene therapy manufacturing for multinational pivotal trials & commercialization
  • Krzysztof Regulski - Head of CMC Project Management, GenSight Biologics, France
1:30pm - 2:00pm 30 mins
Pre-clinical and Clinical Development for Cell, Gene and CART Therapies
Rapid clinical plans and anticipating process change
  • Miguel Forte - CEO, Zelluna Immunotherapy, Norway
2:00pm - 2:30pm 30 mins
Info
Cell, Gene and CART Therapy Bioprocessing
Spotlight Presentation

Use this event to raise your corporate profile and demonstrate your products and services to our targeted, multidisciplinary audience. By joining us in sponsoring and exhibiting at this event, you will be able to:

  • Use an exhibition stand to meet new clients in the main networking area
  • Raise your corporate profile and shape your corporate image with logo placement
  • Ensure market presence as a thought leader with a speaking position

For sponsorship and exhibition opportunities please contact: Kristin Skahan; Email: kristin.skahan@knect365.com


2:00pm - 2:30pm 30 mins
Info
Cell, Gene and CART Therapy Commercialization
Spotlight Presentation

Use this event to raise your corporate profile and demonstrate your products and services to our targeted, multidisciplinary audience. By joining us in sponsoring and exhibiting at this event, you will be able to:

  • Use an exhibition stand to meet new clients in the main networking area
  • Raise your corporate profile and shape your corporate image with logo placement
  • Ensure market presence as a thought leader with a speaking position

For sponsorship and exhibition opportunities please contact: Kristin Skahan; Email: kristin.skahan@knect365.com


2:00pm - 2:30pm 30 mins
Pre-clinical and Clinical Development for Cell, Gene and CART Therapies
Clinical Translation Structure and Partnership
  • Julie Allickson - Director, Regenerative Medicine Clinical Center, Wake Forest Institute for Regenerative Medicine, USA
2:30pm - 3:15pm 45 mins
Afternoon Coffee and Networking
3:15pm - 4:15pm 60 mins
Keynotes
Gene Therapy Keynote
  • Guanping Gao - Professor, Microbiology & Physiological Systems, Penelope Booth Rockwell Professor in Biomedical Research, Co-Director, Li Weibo Institute for Rare Diseases Research, Director, Horae Gene Therapy Center and Vector Core, Scientific Director, UMMS-China Program Office, USA
4:15pm - 5:15pm 60 mins
Keynotes
Keynote Address – The Eulogy of Toby Peach
  • Toby Peach - Theatre Maker, Writer & Director, Toby Peach, UK
5:15pm - 6:45pm 90 mins
Grand Opening of the Poster & Exhibit Hall and Cocktail Reception